American Journal of Cardiology
Volume 99, Issue 7 , Pages 1006-1012 , 1 April 2007

Effect of Inhibition of the Renin-Angiotensin System on Development of Type 2 Diabetes Mellitus (Meta-Analysis of Randomized Trials)

  • Richard Andraws, MD

      Affiliations

    • Division of Cardiovascular Medicine, SUNY-Downstate School of Medicine, Brooklyn, New York
    • ,
  • David L. Brown, MD

      Affiliations

    • Division of Cardiovascular Medicine, SUNY-Stony Brook School of Medicine, Stony Brook, New York.
    • Corresponding Author InformationCorresponding author: Tel: 631-444-3699; fax: 631-444-1054.

Received 3 August 2006 ,Revised 31 October 2006 ,Accepted 31 October 2006.

References 

  1. American Diabetes Association. Economic costs of diabetes in 2002. Diabetes Care. 2003;26:917–932
  2. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456–1462
  3. Ruilope DM. Renoprotection and renin-angiotensin system blockade in diabetes mellitus. Am J Hypertens. 1997;10:325S–331S
  4. Abuissa H, Jones PG, Marso SP, O’Keefe JH. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol. 2005;46:821–826
  5. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. 2005;366:895–906
  6. Meade MO, Richardson WS. Selecting and appraising studies for a systematic review. Ann Intern Med. 1997;127:531–537
  7. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodologic quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408–412
  8. American Diabetes Association. Position statement: standards of medical care in diabetes. Diabetes Care. 2005;28(suppl):S4–S36
  9. World Health Organization. Definition, Diagnosis and Classification of Diabetes and Its Complications: A Report of a WHO Consultation. Geneva, Switzerland: World Health Organization; 1999;
  10. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al Effect of angiotensin-converting inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611–616
  11. Hansson L, Lindholm LH, Ekborn T, Dahlöf T, Lanke J, Scherstén B, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients With Hypertension-2 study. Lancet. 1999;354:1751–1756
  12. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of angiotensin-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Eng J Med. 2000;342:145–153
  13. Dahlöf B, Devereux R, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003
  14. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–2997
  15. Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif JC. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 2003;107:1291–1296
  16. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759–766
  17. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principle results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875–886
  18. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens. 2003;1563–1574
  19. Wing LMH, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GLR, et al A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583–592
  20. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022–2031
  21. The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;350:2058–2068
  22. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–1053
  23. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:343–350
  24. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403
  25. Steyn NP, Mann J, Bennett PH, Temple N, Zimmet P, Tuomilehto J, et al. Diet, nutrition and prevention of type 2 diabetes. Public Health Nutr. 2004;7:147–165
  26. Foreyt JP, Poston WS. The challenge of diet, exercise and lifestyle modification in the management of the obese diabetic patient. Int J Obes Relat Metab Disord. 1999;23(suppl):S5–S11
  27. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA. 2002;288:2880–2883
  28. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072–2077
  29. Togerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention type 2 diabetes in obese patients. Diabetes Care. 2004;27:155–161
  30. Prasad A, Quyyumi AA. Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation. 2004;110:1507–1512
  31. McFarlane SI, Kumar A, Sowers JR. Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol. 2003;91(suppl):30H–37H
  32. Jandeleit KAM, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens. 2005;23:463–473
  33. Ko SH, Kwon HS, Kim SR, Moon SD, Ahn YB, Song KH, et al Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats. Biochem Biophys Res Commun. 2004;316:114–122
  34. Tikellis C, Cooper ME, Thomas MC. Role of the rennin-angiotensin system in the endocrine pancreas: implications for the development of diabetes. Int J Biochem Cell Biol. 2006;38:737–751
  35. The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096–1105

PII: S0002-9149(06)02508-2

doi: 10.1016/j.amjcard.2006.10.068

American Journal of Cardiology
Volume 99, Issue 7 , Pages 1006-1012 , 1 April 2007

Article Tools

* Image Usage & Resolution